TY - JOUR
T1 - Identification of human host factors required for beta-defensin-2 expression in intestinal epithelial cells upon a bacterial challenge
AU - Wozniak, Weronika
AU - Sechet, Emmanuel
AU - Kwon, Yong Jun
AU - Aulner, Nathalie
AU - Navarro, Lionel
AU - Sperandio, Brice
N1 - Acknowledgements
We acknowledge Pr. Philippe Sansonetti and Pr. Reichard for helpful discussions, and Anne Danckaert for analytical support. We thank colleagues from ENS, IP and IPK for critical reading of the manuscript. We also thank IPK members for their warm welcome in Seoul. W.W. received a Ph.D. funding support from PSL University under the program “Investissement d’Avenir” launched by the French Government and implemented by ANR with the reference ANR-10-IDEX-0001-02 PSL. This study received fundings from (i) the French Government “Investissement d’Avenir” program, Labex IBEID, with the reference ANR-10-LABX-62-IBEID, (ii) the French Alliance pour les Sciences de la Vie et de la Santé (AVIESAN), ITMO I3M, (iii) the PSL University, through the PSL pré-maturation program, AMPlify project, with the reference C22-78/2022-425, and (iv) the European Union, through the European Innovation Council Pathfinder Open program, MaxImmun project, with the reference 101129622.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7/4
Y1 - 2024/7/4
N2 - The human intestinal tract is colonized with microorganisms, which present a diverse array of immunological challenges. A number of antimicrobial mechanisms have evolved to cope with these challenges. A key defense mechanism is the expression of inducible antimicrobial peptides (AMPs), such as beta-defensins, which rapidly inactivate microorganisms. We currently have a limited knowledge of mechanisms regulating the inducible expression of AMP genes, especially factors from the host required in these regulatory mechanisms. To identify the host factors required for expression of the beta-defensin-2 gene (HBD2) in intestinal epithelial cells upon a bacterial challenge, we performed a RNAi screen using a siRNA library spanning the whole human genome. The screening was performed in duplicate to select the strongest 79 and 110 hit genes whose silencing promoted or inhibited HBD2 expression, respectively. A set of 57 hits selected among the two groups of genes was subjected to a counter-screening and a subset was subsequently validated for its impact onto HBD2 expression. Among the 57 confirmed hits, we brought out the TLR5-MYD88 signaling pathway, but above all new signaling proteins, epigenetic regulators and transcription factors so far unrevealed in the HBD2 regulatory circuits, like the GATA6 transcription factor involved in inflammatory bowel diseases. This study represents a significant step toward unveiling the key molecular requirements to promote AMP expression in human intestinal epithelial cells, and revealing new potential targets for the development of an innovative therapeutic strategy aiming at stimulating the host AMP expression, at the era of antimicrobial resistance.
AB - The human intestinal tract is colonized with microorganisms, which present a diverse array of immunological challenges. A number of antimicrobial mechanisms have evolved to cope with these challenges. A key defense mechanism is the expression of inducible antimicrobial peptides (AMPs), such as beta-defensins, which rapidly inactivate microorganisms. We currently have a limited knowledge of mechanisms regulating the inducible expression of AMP genes, especially factors from the host required in these regulatory mechanisms. To identify the host factors required for expression of the beta-defensin-2 gene (HBD2) in intestinal epithelial cells upon a bacterial challenge, we performed a RNAi screen using a siRNA library spanning the whole human genome. The screening was performed in duplicate to select the strongest 79 and 110 hit genes whose silencing promoted or inhibited HBD2 expression, respectively. A set of 57 hits selected among the two groups of genes was subjected to a counter-screening and a subset was subsequently validated for its impact onto HBD2 expression. Among the 57 confirmed hits, we brought out the TLR5-MYD88 signaling pathway, but above all new signaling proteins, epigenetic regulators and transcription factors so far unrevealed in the HBD2 regulatory circuits, like the GATA6 transcription factor involved in inflammatory bowel diseases. This study represents a significant step toward unveiling the key molecular requirements to promote AMP expression in human intestinal epithelial cells, and revealing new potential targets for the development of an innovative therapeutic strategy aiming at stimulating the host AMP expression, at the era of antimicrobial resistance.
KW - Antimicrobial peptide
KW - Bacterial challenge
KW - Beta-defensin-2
KW - Gene regulation
KW - Human intestinal epithelial cell
KW - Innate immunity
UR - http://www.scopus.com/inward/record.url?scp=85197559210&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38965312/
U2 - 10.1038/s41598-024-66568-y
DO - 10.1038/s41598-024-66568-y
M3 - Article
C2 - 38965312
AN - SCOPUS:85197559210
SN - 2045-2322
VL - 14
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 15442
ER -